Citius Pharmaceuticals (CTXR) Interest Coverage Ratio (2010 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Interest Coverage Ratio came in at 4.68 in Q1 2026, up 92.38% YoY from 2.43 in Q1 2025, and down 256.96% on a QoQ basis from 1.31 in Q4 2025.
Citius Pharmaceuticals (CTXR) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 17 years of Interest Coverage Ratio data on file, last reported at 4.68 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 92.38% year-over-year to 4.68 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.49 (up 96.38% YoY) and the FY2025 annual result came in at 0.58, up 92.53% from the prior year.
- Interest Coverage Ratio fell to 4.68 in Q1 2026, from 1.31 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 1.31 in Q4 2025 to a low of 1319.79 in Q4 2024.
- A 5-year average of 142.21 and a median of 20.2 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio plunged 6433.57% — and 2025, when it soared 99.9%.
- Tracing CTXR's Interest Coverage Ratio over 5 years: stood at 42.84 in 2022, then soared by 52.85% to 20.2 in 2023, then sank by 6433.57% to 1319.79 in 2024, then soared by 99.9% to 1.31 in 2025, then tumbled by 256.96% to 4.68 in 2026.
- The last three Interest Coverage Ratio figures came in at 4.68 (Q1 2026), 1.31 (Q4 2025), and 88.33 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | Citius Pharmaceuticals | 15.60 Mn | 15.60 Mn | 1.00 Mn | -50.63 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.68 |
| Dec 31, 2025 | -1.31 |
| Sep 30, 2025 | -88.33 |
| Jun 30, 2025 | -45.92 |
| Mar 31, 2025 | -61.42 |
| Dec 31, 2024 | -1,319.79 |
| Sep 30, 2024 | -2.05 |
| Jun 30, 2024 | -574.85 |
| Mar 31, 2024 | -10.28 |
| Dec 31, 2023 | -20.20 |
| Sep 30, 2023 | -180.15 |
| Jun 30, 2023 | -10.64 |
| Mar 31, 2023 | -14.23 |
| Dec 31, 2022 | -42.84 |
| Sep 30, 2022 | -8.68 |
| Jun 30, 2022 | -29.43 |
| Mar 31, 2022 | -2.76 |
| Sep 30, 2021 | -4,216.57 |
| Jun 30, 2021 | -0.66 |
| Mar 31, 2021 | -1.57 |